You just read:

Mirati Therapeutics To Present Pre-Clinical And Initial Clinical Data For MRTX849, A KRAS G12C Inhibitor, At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics

News provided by

Mirati Therapeutics, Inc.

Oct 17, 2019, 09:00 ET